Results 41 to 50 of about 847 (163)

Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends. [PDF]

Headache
Abstract Objective To evaluate changes in public interest in calcitonin gene‐related peptide therapies associated with major product lifecycle milestones using online search data from the United States and Europe. Background Calcitonin gene‐related peptide therapies have transformed migraine treatment, but the impact of key product lifecycle milestones
Ong B, Ahdab JE, Thompson N, Bhagat M, Ney J, Weathers AL.   +5 more
europepmc   +2 more sources

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

, 2021
Background: Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist for the preventive treatment of migraine. Methods: In the double-blind, phase 3 ADVANCE trial, participants with 4–14 migraine days/month were ...
Schwedt T. J., Lipton R. B., Miceli R., Severt L., Silberstein S. D., Trugman J. M., Tassorelli C., Dabruzzo B., Finnegan M., Ailani J., Guo H., Lu K., Jessica Ailani, Cristina Tassorelli, Michelle Finnegan, Todd J Schwedt, Brett Dabruzzo, Stephen D Silberstein, Richard B Lipton, Hua Guo, Rosa Miceli, Kaifeng Lu, Lawrence Severt, Joel M Trugman   +23 more
core   +1 more source

Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine

, 2020
Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clini- cal investigation for preventive treatment of migraine.
Martelletti, P., Capi, M., Lionetto, L., Curto, M., Cipolla, F.   +4 more
core   +1 more source

Neurologic Symptoms and Cerebrovascular Events During Atogepant Therapy: A Case Series with Contextual Comparison with a Non-Gepant-Treated Migraine Cohort. [PDF]

J Clin Med
Background: CGRP contributes to cerebrovascular regulation, mainly based on experimental and translational data; human evidence remains limited. Gepants, including atogepant, are effective migraine preventives and achieve partial penetration across the ...
Göbel CH, Heinze A, Heinze-Kuhn K, Cirkel A, Göbel H.   +4 more
europepmc   +2 more sources

Supplementary Table S1: Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial

, 2021
Supplementary Table 1. Atogepant and Sumatriptan: No Clinically Relevant Drug-Drug Interactions in a Randomized, Open-label, Crossover Trial Intervention ...
Abhijeet Jakate (8832242), Antonia Periclou (8832254), Ramesh Boinpally (8832245), Matthew Butler (387341)   +3 more
core   +1 more source

Blocking the CGRP Receptor: Differences across Human Vascular Beds

Pharmaceuticals, 2023
Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for the treatment of migraine. Here, the effect of the small-molecule CGRP receptor antagonist zavegepant (0.1 nM–1 µM) on CGRP-induced relaxation in ...
Tessa de Vries, Deirdre M. Boucherie, Antoon van den Bogaerdt, A. H. Jan Danser, Antoinette MaassenVanDenBrink   +4 more
doaj   +1 more source

Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Evaluate early functional improvements with the preventive migraine treatment atogepant using Activity Impairment in Migraine–Diary (AIM‐D) individual and activity limitation items, and complete improvement in AIM‐D Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores assessed weekly during the first 4 ...
Richard B. Lipton, Pranav Gandhi, Andreas R. Gantenbein, Brett Dabruzzo, Karen Carr, Jonathan Stokes, Molly Duan, Rashmi B. Halker Singh, Hsiangkuo Yuan, Dawn C. Buse   +9 more
wiley   +1 more source

Distribution and target engagement of peripherally administered fremanezumab in the cerebrospinal fluid of healthy volunteers

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Our objective was to describe the distribution of fremanezumab to the cerebrospinal fluid (CSF) in healthy volunteers, and investigate its engagement and stabilization of its target, calcitonin gene‐related peptide (CGRP). Fremanezumab is a CGRP‐targeting monoclonal antibody approved for migraine prevention.
Jacki Rorabaugh, Edward Hellriegel, Juline Bryson, Ryan Tiver, Hang Zeng, Xiaofeng Lu, Steve Barash, Giulia Ghibellini, Olga Szilagyi, Ignacio Echenique, Andrew H. Ahn, Peter J. Goadsby, Laura Rabinovich‐Guilatt   +12 more
wiley   +1 more source

Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial

, 2023
Background: Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine.
Laszlo Mechtler, Mechtler, Laszlo, Rashmi B. Halker Singh, Halker Singh, Rashmi B., Gandhi, Pranav, Dabruzzo, Brett, Jonathan Stokes, Brett Dabruzzo, Stokes, Jonathan, Sung Yun Yu, Richard B. Lipton, Jennifer McVige, Ma, Julia, Julia Ma, Lipton, Richard B., Ashina, Messoud, Pranav Gandhi, McVige, Jennifer, Messoud Ashina, Yu, Sung Yun   +19 more
core   +1 more source

Longitudinal effects of CGRP‐targeting migraine therapies on blood pressure and body mass index: A 12‐month retrospective analysis

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare blood pressure (BP) and body mass index (BMI) trajectories associated with individual calcitonin gene‐related peptide (CGRP)‐targeting migraine therapies versus matched CGRP‐unexposed controls. Background CGRP is a potent vasodilator with established roles in vascular homeostasis and metabolic regulation.
Phillip Phan, Scott Keith, Michael Li, Richard Hass, Wan‐Jen Hsieh, Michael Marmura, Hsiangkuo Yuan   +6 more
wiley   +1 more source